Optimizing immune recognition - Group Boes


My lab explores mechanisms that drive immune recognition in human disease. It is becoming increasingly clear that many diseases have an inflammatory component to them that may be treatable by immune response modification. Cancer is one such disease, that moreover touches on many aspects of immune recognition. Our approach to finding mechanisms in human disease is to study common traits in diseases of limited complexity (primary immunodeficiencies presenting with autoinflammation) and conditions of increasing complexity (rheumatoid disorders, cancer). From 2003-2008, my laboratory was located at Harvard Medical School/Brigham and Women’s Hospital in Boston, USA. Since 2008, we are located at the UMC-Utrecht.

Research programs

Infection and Immunity

Child Health


Research interests

  • Immunology
  • Antigen presentation
  • Immune recognition
  • Human disease
  • Pediatric


Marianne Boes


Related websites

    Research gate  Loop Frontiers 


  1. Bystander T-cells support T-cell activation by controlling the release of dendritic cell-derived immune-stimulatory extracellular vesicles. Lindenbergh MFS, Koerhuis DGJ, Borgh EGF, van ‘t Veld EM, Driedonks TAP, Wubbolts R, Stoorvogel W, Boes M. Front Immunol. 2019 Mar 12; 10:448. IF: 4.716; PMID: 30915085 View
  2. Nedd4 Binding Protein 1 (N4BP1) and TNFAIP3 Interacting Protein 1 (TNIP1) control MHC-1 display in neuroblastoma. Spel L, Nieuwenhuis J, Haarsma R, Stickel E, Bleijerveld OB, Altelaar M, Boelens JJ, Brummelkamp TR, Nierkens S, Boes M. Cancer Res. 2018 Dec 1;78(23):6621-6631. IF: 8.378; PMID: 30213788 View
  3.  Proline-serine-threonine phosphatase interacting protein 1 (PSTPIP1) controls immune synapse stability in human T cells. Janssen WJM, Grobarova V, Leleux J, Jongeneel L, van Gijn M, van Montfrans JM, Boes M.  J Allergy Clin Immunol. 2018 Dec;142(6):1947-1955. IF: 14.110; PMID: 29432774 View
  4. Fcg receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Flinsenberg TW, Compeer EB, Koning D, Klein M, Amelung FJ, van Baarle D, Boelens JJ, Boes M. Blood. 2012 Dec 20;120(26):5163-72. IF: 16.562; PMID: 23093620 View
  5.  T cell engagement of dendritic cells rapidly rearranges MHC class II transport. Boes M, Cerny J, Massol R, Op den Brouw M, Kirchhausen T, Chen J, Ploegh HL.  Nature. 2002 Aug 29;418(6901):983-8 IF: 43.070; PMID: 12198548. View

View all publications 


van Creveldkliniek

Prof Dr Roger Schutgens, Dr. Kathelijn Fischer

Princes Maxima Centrum voor Kinderoncologie

Dr. Friederike Meyer-Wentrup

UU Veterinary Department

Prof. Dr. Willem Stoorvogel

Molecular Cancer Research

Dr. Eric Kalkhoven

Boston Children's Hospital

Prof. Dr. Hidde Ploegh




Lymph&Co Grant award Marianne Boes (2019)

iGEM worldwide competition UU/UMCU team 2 bronze medals  (2018)

Tom Voute Young Investigator Award Lotte Spel (2016)

UMC news

2019 Sep: Onderzoek naar vaccin voor lymfeklierkanker van start

Education & Courses

Educational Comittee Life Sciences

Since 2017, Marianne Boes is a staff member of the Educational Comittee Life Sciences that assesses and ensures the quality of education of the master's programmes within the Graduate School of Life Sciences.